Latest Financial Health News

Ardiden Limited advances exploration at its Pickle Lake Gold Project in Northwest Ontario, focusing on high-potential prospects while maintaining a robust financial position with A$11.4 million in cash and no debt.

Openn Negotiation Ltd has reported a remarkable financial turnaround in its half-year results to December 2024, shifting from a significant loss to a modest profit while divesting key subsidiaries.

Orpheus Uranium Limited reported a net cash outflow from operations and investing in the June quarter but strengthened its cash position through financing activities, extending its funding runway to over seven quarters.

Magnis Energy Technologies progresses detailed engineering on its Nachu Graphite Project and moves to fast track US anode material production, while navigating ASX suspension and IM3NY bankruptcy fallout.

CurveBeam AI reported a solid 18% increase in purchase orders for FY25, alongside record cash receipts and positive operational cash flow in Q4. The company is also advancing a significant vendor financing facility to support growth in key markets.

NGX Limited progresses its Malingunde graphite project with technical studies and stakeholder engagement, while uranium exploration permits advance in Namibia. The company stands to benefit from new US anti-dumping tariffs on Chinese graphite imports.

Vitrafy Life Sciences reported robust progress in Q4 FY2025, advancing its cryopreservation technology and commercial partnerships while preparing for a pivotal product launch in FY2026.

Immutep Limited advances its pivotal Phase III lung cancer trial and reports promising results across multiple oncology and autoimmune programs, supported by a solid cash position to fund operations through 2026.

Spectur Limited reports a positive operating cash flow for Q4 FY25, driven by revenue growth and cost-cutting, alongside strategic investments in cloud and connectivity technology.

Rand Mining Ltd reported solid gold production of 8,916 ounces in the June 2025 quarter, alongside improved cash flow and ongoing exploration success at key Western Australian projects.

Centuria Capital No. 2 Fund confirms full compliance with note terms and stable loan positions in its Q4 FY25 report, reassuring investors amid a steady operational quarter.

Biotron Limited has successfully raised $1.27 million through an entitlement issue to fund its antiviral drug development, including a promising Hepatitis B compound that cleared its initial animal safety study.